SEARCH:   Advanced

Blood, 15 June 2008, Vol. 111, No. 12, pp. 5637-5645. Prepublished online as a Blood First Edition Paper on April 16, 2008; DOI 10.1182/blood-2007-05-092866. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-05-092866v1 111/12/5637    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Renukaradhya, G. J. Articles by Brutkiewicz, R. R. PubMed PubMed Citation Articles by Renukaradhya, G. J. Articles by Brutkiewicz, R. R. Related Collections Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma Gourapura J. Renukaradhya13, Masood A. Khan13, Marcus Vieira13, Wenjun Du4, Jacquelyn Gervay-Hague4, and Randy R. Brutkiewicz13 1 Department of Microbiology and Immunology, Indiana University School of Medicine, 2 The Walther Oncology Center, and 3 The Walther Cancer Institute, Indianapolis, IN; and 4 Department of Chemistry, University of California, Davis Natural killer T (NKT) cells are a T-cell subpopulation known to possess immunoregulatory functions and recognize CD1d molecules. The majority of NKT cells express an invariant T-cell receptor (TCR) chain rearrangement (V14J18 in mice; V24J18 in humans) and are called type I NKT cells; all other NKT cells are type II. In the current study, we have analyzed the roles for these NKT-cell subsets in the host's innate antitumor response against a murine B-cell lymphoma model in vivo. In tumor-bearing mice, we found that type I NKT cells conferred protection in a CD1d-dependent manner, whereas type II NKT cells exhibited inhibitory activity. Pro- and anti-inflammatory cytokines secreted by splenocytes from tumor-bearing mice correlated with tumor progression. Myeloid cells (CD11b+Gr1+) were present in large numbers at the tumor site and in the spleen of tumor-bearing type I NKT–deficient mice, suggesting that antitumor immunosurveillance was inhibited by CD11b+Gr1+ cells. Overall, these data suggest that there are distinct roles for NKT-cell subsets in response to a B-cell lymphoma in vivo, pointing to potential novel targets to be exploited in immunotherapeutic approaches against blood cancers. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020